Taken together, these findings demonstrated that the ACh/ChAT increase was, at least in part, an adaptive response upon EGFR-TKI treatment, although we could not exclude the possibility of intrinsically high levels of the short ChAT isoform in tumor cells. The gene discussed is EGFR; the disease is neoplasm.